AbbVie Inc. has announced an update on their global Phase 3 VERONA trial, which assessed the efficacy of venetoclax in combination with azacitidine for the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS). The trial did not achieve its primary endpoint of overall survival, with a hazard ratio of 0.908 and a p-value of 0.3772. There were no new safety signals observed during the study. Results from the VERONA trial are scheduled to be presented at a future medical congress or publication. This outcome does not affect any of the currently approved indications for venetoclax. More detailed information about the trial can be accessed on ClinicalTrials.gov.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.